Clinical trials: Cavaterm™ System
Cavaterm™ System
CavatermTM for Idiopathic Functional Menometrorraghia
The prevalence of menometrorrhagia is estimated at 11% to 13% in the general population and increases with age to reach 24% in 36-40 year olds. It is the leading cause of gynecological consultations.
- Trial name
- CAVATERM (NCT07205146)
- Testing
- menometrorrhagia
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon